Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT06188702
Registration number
NCT06188702
Ethics application status
Date submitted
18/12/2023
Date registered
3/01/2024
Date last updated
13/10/2026
Titles & IDs
Public title
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
Query!
Scientific title
A Phase 1/2, Open-label, Multicenter Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of S095035 (MAT2A Inhibitor) as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Homozygous Deletion of MTAP
Query!
Additional trial identifiers [1]
0
0
2025-521249-25-00
Query!
Additional trial identifiers [2]
0
0
CL1-95035-001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
MTAP-deleted Solid Tumors
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Biliary tree (gall bladder and bile duct)
Query!
Cancer
0
0
0
0
Query!
Lung - Non small cell
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of the intervention or exposure
Treatment: Drugs - S095035
Treatment: Drugs - TNG462
Experimental: Phase 1 Arm 1 - S095035 single-agent dose escalation -
Experimental: Phase 1 Arm 2 - S095035-TNG462 combination dose escalation -
Experimental: Phase 2 Arm 1a NSCLC - S095035 single-agent dose expansion - Non-Small Cell Lung Cancer
Experimental: Phase 2 Arm 1b BTC - S095035 single-agent dose expansion - Biliary Tract Cancer
Experimental: Phase 2 Arm 1c PDAC - S095035 single-agent dose expansion - Pancreatic Ductal Adenocarcinoma
Experimental: Phase 2 Arm 1d Basket arm - S095035 single-agent dose expansion -
Experimental: Phase 2 Arm 2a BTC - S095035-TNG462 combination dose expansion - Biliary Tract Cancer
Experimental: Phase 2 Arm 2b Gastroesophageal - S095035-TNG462 combination dose expansion -
Experimental: Phase 2 Arm 2c PDAC - S095035-TNG462 combination dose expansion - Pancreatic Ductal Adenocarcinoma
Treatment: Drugs: S095035
S095035 will be taken orally every day in 28-day cycles.
Treatment: Drugs: TNG462
TNG462 will be taken orally every day in 28-day cycles.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Description of the comparator or control
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Dose limiting toxicities (DLTs)
Query!
Assessment method [1]
0
0
Phase 1 only
Query!
Timepoint [1]
0
0
Through cycle 1 (each cycle is 28 days)
Query!
Primary outcome [2]
0
0
Total number of adverse events (AEs)
Query!
Assessment method [2]
0
0
Phase 1 only
Query!
Timepoint [2]
0
0
Through the Safety Follow-up Visit (until 30 days after the last dose of study treatment) approximately 5 years
Query!
Primary outcome [3]
0
0
Total number of serious adverse events (SAEs)
Query!
Assessment method [3]
0
0
Phase 1 only
Query!
Timepoint [3]
0
0
Through the Safety Follow-up Visit (until 30 days after the last dose of study treatment) approximately 5 years
Query!
Primary outcome [4]
0
0
Objective response rate (ORR)
Query!
Assessment method [4]
0
0
Phase 2 only; Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as per the investigator's assessment and by blinded independent central review (BICR)
Query!
Timepoint [4]
0
0
Through the end of the study (approximately 5 years)
Query!
Secondary outcome [1]
0
0
Area under the concentration-vs-time curve (AUC) from 0 to time of last measurable concentration (AUC0-t)
Query!
Assessment method [1]
0
0
Phase 1 and 2
Query!
Timepoint [1]
0
0
Through the last dose of study treatment (approximately 5 years)
Query!
Secondary outcome [2]
0
0
AUC from 0 to infinity (AUC0-8)
Query!
Assessment method [2]
0
0
Phase 1 and 2
Query!
Timepoint [2]
0
0
Through the last dose of study treatment (approximately 5 years)
Query!
Secondary outcome [3]
0
0
AUC over 1 dosing interval at steady state (AUCtau,ss)
Query!
Assessment method [3]
0
0
Phase 1 and 2
Query!
Timepoint [3]
0
0
Through the last dose of study treatment (approximately 5 years)
Query!
Secondary outcome [4]
0
0
Time to maximum concentration (Tmax)
Query!
Assessment method [4]
0
0
Phase 1 and 2
Query!
Timepoint [4]
0
0
Through the last dose of study treatment (approximately 5 years)
Query!
Secondary outcome [5]
0
0
Maximum concentration (Cmax)
Query!
Assessment method [5]
0
0
Phase 1 and 2
Query!
Timepoint [5]
0
0
Through the last dose of study treatment (approximately 5 years)
Query!
Secondary outcome [6]
0
0
Trough concentration (Ctrough)
Query!
Assessment method [6]
0
0
Phase 1 and 2
Query!
Timepoint [6]
0
0
Through the last dose of study treatment (approximately 5 years)
Query!
Secondary outcome [7]
0
0
Half-life (t½)
Query!
Assessment method [7]
0
0
Phase 1 and 2
Query!
Timepoint [7]
0
0
Through the last dose of study treatment (approximately 5 years)
Query!
Secondary outcome [8]
0
0
Apparent volume of distribution (Vd/F)
Query!
Assessment method [8]
0
0
Phase 1 and 2
Query!
Timepoint [8]
0
0
Through the last dose of study treatment (approximately 5 years)
Query!
Secondary outcome [9]
0
0
Apparent clearance (CL/F)
Query!
Assessment method [9]
0
0
Phase 1 and 2
Query!
Timepoint [9]
0
0
Through the last dose of study treatment (approximately 5 years)
Query!
Secondary outcome [10]
0
0
Change from baseline in plasma concentrations of S-adenosylmethionine (SAM) and/or tumor symmetric dimethylarginine (SDMA) residues during treatment
Query!
Assessment method [10]
0
0
Phase 1 only
Query!
Timepoint [10]
0
0
Through the last dose of study treatment (approximately 5 years)
Query!
Secondary outcome [11]
0
0
Objective response rate (ORR)
Query!
Assessment method [11]
0
0
Phase 1 only; Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as per the investigator's assessment
Query!
Timepoint [11]
0
0
Through the end of the study (approximately 5 years)
Query!
Secondary outcome [12]
0
0
Best overall response (BOR)
Query!
Assessment method [12]
0
0
Phase 1 and 2; Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as per the investigator's assessment for Phase 1 and 2, and by BICR only for Phase 2.
Query!
Timepoint [12]
0
0
Through the end of the study (approximately 5 years)
Query!
Secondary outcome [13]
0
0
Clinical benefit rate (CBR)
Query!
Assessment method [13]
0
0
Phase 1 and 2; CBR=complete response \[CR\]+partial response \[PR\]+stable disease \[SD\] ) =6 months, Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as per the investigator's assessment for Phase 1 and 2, and by BICR only for Phase 2
Query!
Timepoint [13]
0
0
Through the end of the study (approximately 5 years)
Query!
Secondary outcome [14]
0
0
Duration of response (DOR)
Query!
Assessment method [14]
0
0
Phase 1 and 2; Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as per the investigator's assessment for Phase 1 and 2, and by BICR only for Phase 2. The time from date of first documented confirmed CR or confirmed PR to date of first documented disease progression or death due to any cause.
Query!
Timepoint [14]
0
0
Through the end of the study (approximately 5 years)
Query!
Secondary outcome [15]
0
0
Time to response (TTR)
Query!
Assessment method [15]
0
0
Phase 1 and 2; Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as per the investigator's assessment for Phase 1 and 2, and by BICR only for Phase 2. The time from the date of randomization to date of first documented confirmed complete response (CR) or confirmed partial response (PR).
Query!
Timepoint [15]
0
0
Through the end of the study (approximately 5 years)
Query!
Secondary outcome [16]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [16]
0
0
Phase 2 Only; Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as assessed by investigator and by BICR
Query!
Timepoint [16]
0
0
Through the end of the study (approximately 5 years)
Query!
Secondary outcome [17]
0
0
Overall Survival (OS)
Query!
Assessment method [17]
0
0
Phase 2 Only; Per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or Response Assessment in Neuro-oncology (RANO) 2.0 criteria as assessed by investigator and by BICR
Query!
Timepoint [17]
0
0
Through the end of the study (approximately 5 years)
Query!
Secondary outcome [18]
0
0
Total number of adverse events (AEs)
Query!
Assessment method [18]
0
0
Phase 2 Only
Query!
Timepoint [18]
0
0
Through the Safety Follow-up Visit (until 30 days after the last dose of study treatment) approximately 5 years
Query!
Secondary outcome [19]
0
0
Total number of serious adverse events (SAEs)
Query!
Assessment method [19]
0
0
Phase 2 Only
Query!
Timepoint [19]
0
0
Through the Safety Follow-up Visit (until 30 days after the last dose of study treatment) approximately 5 years
Query!
Secondary outcome [20]
0
0
Number of dose interruptions
Query!
Assessment method [20]
0
0
Phase 2 Only
Query!
Timepoint [20]
0
0
Through the last dose of study treatment (approximately 5 years)
Query!
Secondary outcome [21]
0
0
Number of dose reductions
Query!
Assessment method [21]
0
0
Phase 2 Only
Query!
Timepoint [21]
0
0
Through the last dose of study treatment (approximately 5 years)
Query!
Secondary outcome [22]
0
0
Dose intensity
Query!
Assessment method [22]
0
0
Phase 2 Only
Query!
Timepoint [22]
0
0
Through the last dose of study treatment (approximately 5 years)
Query!
Eligibility
Key inclusion criteria
* Estimated life expectancy =3 months.
* ECOG PS 0-1
* Participants able to comply with highly effective method of birth control requirements.
* Participants with histologically confirmed advanced or metastatic solid tumor's (excluding central nervous system tumors other than IDHwt glioblastoma), with measurable disease as per RECIST 1.1 or RANO 2.0 criteria for participants with IDHwt glioblastoma, that have progressed after at least one prior treatment regimen given for advanced/metastatic disease, and for whom additional effective standard therapy is not available. Patients in China with IDHwt glioblastoma will not be included.
* Participants with pre-existing documented MTAP homozygous gene deletion in their tumor tissue, determined using a next generation sequencing in vitro diagnostic test prior to screening.
* Phase 1 only - Participants (except IDHwt glioblastoma) willing to undergo paired fresh biopsy (pre-treatment and on-treatment) procedure. Exceptions may be made for feasibility and safety concerns. IDHwt glioblastoma must provide archival tissue from most recent surgery or biopsy.
* Adequate organ functions.
* Phase 2 only - Participants in dose expansion, except those with IDHwt glioblastoma, must provide newly collected tumor biopsies at screening. If not medically feasible archival tissue may be used, provided it was collected within 3 months before study entry and no treatment has been received since the most recent biopsy.
* Phase 2 only - Participants with IDHwt glioblastoma must provide archival tissue from their most recent surgery or biopsy, collected before screening.
* Phase 2 only - Participants in China who are to be considered for enrollment in the single agent dose expansion Arms and who have a pre-existing, documented cyclin-dependent kinase inhibitor 2A (CDKN2A) homozygous gene deletion in their tumor tissue (confirmed by an NGS IVD test), but do not have homozygous MTAP deletion reported, will need to be pre-screened to confirm homozygous MTAP deletion. Pre screening for homozygous MTAP deletion will be conducted using a central NGS IVD test using an archival tumor tissue, preferably the most recent and not older than 3 years.
* Phase 2 Arm 1a only - Participants with histologically or cytologically confirmed metastatic or unresectable locally advanced NSCLC with homozygous deletion of MTAP, with measurable disease as per RECIST version 1.1, who have progressed or experienced disease recurrence during or after at least 1 prior line of standard-of-care systemic therapy in the advanced/metastatic setting.
* Phase 2 Arm 1b only - Participants with histologically or cytologically confirmed metastatic or unresectable locally advanced BTC with homozygous deletion of MTAP, who have progressed or experienced disease recurrence during or after at least 1 prior line of standard-of-care systemic therapy in the advanced/metastatic setting.
* Phase 2 Arm 1c only - Participants with histologically or cytologically confirmed metastatic or unresectable locally advanced PDAC with homozygous deletion of MTAP, who have progressed or experienced disease recurrence during or after at least 1 prior line of standard-of-care systemic therapy in the advanced/metastatic setting.
* Phase 2 Arm 1d only - Participants with any other locally advanced or metastatic malignancies with homozygous deletion of MTAP, who have received and progressed of experienced recurrence during or after receiving at least 1 prior line of standard-of-care systemic therapy in the advanced/metastatic setting.
* Phase 2 Arm 2a only - Participants with histologically or cytologically confirmed metastatic or unresectable locally advanced BTC with homozygous deletion of MTAP, who have progressed or experienced disease recurrence during or after receiving at least 1 prior line of standard-of care systemic therapy in the advanced/metastatic setting.
* Phase 2 Arm 2b only - Participants with histologically or cytologically confirmed metastatic or unresectable locally advanced gastroesophageal cancer with homozygous deletion of MTAP, who have progressed or experienced disease recurrence during or after receiving at least 1 prior line of standard-of-care systemic therapy in the advanced/metastatic setting.
* Phase 2 Arm 2c only - Participants with histologically or cytologically confirmed metastatic or unresectable locally advanced PDAC with homozygous deletion of MTAP, who have progressed or experienced disease recurrence during or after receiving at least 1 prior line of standard-of-care systemic therapy in the advanced/metastatic setting.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
* Inability to take an orally administered drug, or medical disorder or prior surgical resection that may affect the absorption of the study drug.
* Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that the Sponsor's Medical monitor and investigator agree and document that it should not be exclusionary.
* Known prior severe hypersensitivity to any component of the study drug formulation.
* Major surgery within 4 weeks prior to the first study drug administration or participants who have not recovered from side effects of the surgery.
* Have a known history of Gilbert's syndrome.
* Participants with a known clinically significant cardiovascular disease or condition.
* Participants with thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within 4 weeks prior to first IMP administration.
* Active brain metastases.
* Participants who have received systemic anticancer treatment or radiotherapy less than 2 weeks before the first dose of study drug
* Pregnant or lactating women.
* Women of childbearing potential who have a positive pregnancy test within 7 days prior to the first day of study drug administration.
* History of gastrointestinal perforation and /or fistula or aorto-esophageal fistula within 6 months prior to first study drug intake.
* Severe or uncontrolled active acute or chronic infection.
* Participants who have already received a MAT2A or PRMT5 inhibitor.
* A medical condition that results in increased clinically significant photosensitivity (e.g., solar urticaria, lupus erythematosus, etc.).
* Participants who are scheduled to receive the S095035-TNG462 combination, with a known clinically significant ophthalmologic disease, including:
* Prior history of drug-induced or toxic retinopathy or optic neuropathy
* Uncontrolled glaucoma
* Pre-existing macular degeneration
* Ongoing Grade =2 retinopathy, optic neuropathy, or optic neuritis
* Other known active retinal pathology
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/04/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/05/2027
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
61
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Query!
Recruitment hospital [1]
0
0
Scientia Clinical Research - Randwick
Query!
Recruitment hospital [2]
0
0
The Alfred - Prahran
Query!
Recruitment hospital [3]
0
0
Townsville University Hospital - Douglas
Query!
Recruitment hospital [4]
0
0
Royal Hobart Hospital - Hobart
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
0
0
3004 - Prahran
Query!
Recruitment postcode(s) [3]
0
0
4812 - Douglas
Query!
Recruitment postcode(s) [4]
0
0
7000 - Hobart
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Florida
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Indiana
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Ohio
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Tennessee
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Texas
Query!
Country [6]
0
0
France
Query!
State/province [6]
0
0
Bordeaux
Query!
Country [7]
0
0
France
Query!
State/province [7]
0
0
Dijon
Query!
Country [8]
0
0
Germany
Query!
State/province [8]
0
0
Ulm
Query!
Country [9]
0
0
Italy
Query!
State/province [9]
0
0
Milan
Query!
Country [10]
0
0
Italy
Query!
State/province [10]
0
0
Rozzano
Query!
Country [11]
0
0
Italy
Query!
State/province [11]
0
0
Verona
Query!
Country [12]
0
0
Japan
Query!
State/province [12]
0
0
Aichi
Query!
Country [13]
0
0
Japan
Query!
State/province [13]
0
0
Ehime
Query!
Country [14]
0
0
Japan
Query!
State/province [14]
0
0
Tokyo
Query!
Country [15]
0
0
Spain
Query!
State/province [15]
0
0
Madrid
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Servier Bio-Innovation LLC
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
Institut de Recherches Internationales Servier
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Commercial sector/industry
Query!
Name [2]
0
0
Tango Therapeutics, Inc.
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a first-in-human Phase 1/2, multicenter, open-label study of S095035 as single-agent, or in combination with TNG462 in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP who have failed to respond to or have progressed after at least 1 prior treatment regimen, and for whom additional effective standard treatment is not available. S095035 is an oral methionine adenosyltransferase 2A \[MAT2A\] inhibitor. TNG462 is a protein arginine N-methyltransferase 5 \[PRMT5\] inhibitor.
Query!
Trial website
https://clinicaltrials.gov/study/NCT06188702
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Institut de Recherches Internationales Servier (I.R.I.S.), Clinical Studies Department
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
+33 1 55 72 60 00
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.
Access can be requested for all interventional clinical studies:
* used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
* where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.
In addition, access can be requested for all interventional clinical studies in patients:
* sponsored by Servier
* with a first patient enrolled as of 1 January 2004 onwards
* for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
After Marketing Authorization in EEA or US if the study is used for the approval.
Query!
Available to whom?
Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: http://clinicaltrials.servier.com/
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT06188702
Download to PDF